Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17175252 | 0.96 | NAMPT (0.43) | LMNAPKMHSD17B10PSMB5POLB | |
| SCHEMBL14868081 | 0.94 | NAMPT (0.44) | LMNAPKMHSD17B10PSMB5POLB | |
| SCHEMBL254148 | 0.91 | HSD17B10 (0.49) | LMNAPKMHSD17B10PSMB5POLB | |
| SCHEMBL11990337 | 0.89 | MAPT (0.45) | LMNAPKMMAPTHPGDNAMPT | |
| SCHEMBL19703688 | 0.86 | PTGS1 (0.50) | LMNAPKMPOLBMAPTHPGD | |
| SCHEMBL14984835 | 0.86 | PTGS1 (0.49) | LMNAPKMHSD17B10POLBMAPT | |
| SCHEMBL19116815 | 0.86 | PTGS1 (0.49) | LMNAPKMMAPTHPGDNAMPT | |
| SCHEMBL21648875 | 0.86 | PTGS1 (0.45) | LMNAPKMPOLBMAPTHPGD | |
| SCHEMBL14868090 | 0.86 | NAMPT (0.41) | LMNAPKMHSD17B10PSMB5POLB | |
| SCHEMBL17740044 | 0.85 | LMNA (0.52) | LMNAPKMHSD17B10PSMB5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103271-A2 | NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE | HANMI PHARM. CO., LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| WO-2020109526-A2 | OXYNTOMODULIN PEPTIDE ANALOG FORMULATIONS | Opko Ireland Global Holdings, Ltd. (KY) | 2020-06-04 | — | — | WO | disclosed |
| US-10626146-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190194254-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2019-06-27 | — | — | US | disclosed |
| US-20190016756-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
| WO-2014086961-A1 | CARRIER-LINKED PROSTANOID PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2014-06-12 | — | — | WO | disclosed |
| US-8367607-B2 | Oxyntomodulin peptide analogue | ELI LILLY AND COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110152182-A1 | OXYNTOMODULIN PEPTIDE ANALOGUE | ELI LILLY AND COMPANY (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152181-A1 | OXYNTOMODULIN PEPTIDE ANALOGUE | ELI LILLY AND COMPANY (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194254-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | LMNA 1144/4885PKM 4281/4885HSD17B10 4612/4885 |
| US-10626146-B2 | α4β7 thioether peptide dimer antagonists | EPCAM, SELPLG, VCAM1 | LMNA 4672/4885PKM 3764/4885HSD17B10 4098/4885 |
| US-20110152182-A1 | OXYNTOMODULIN PEPTIDE ANALOGUE | GLP1R, IAPP, GIPR | LMNA 4719/4885PKM 4594/4885HSD17B10 1428/4885 |
| US-20110152181-A1 | OXYNTOMODULIN PEPTIDE ANALOGUE | GLP1R, IAPP, GPR119 | LMNA 4730/4885PKM 4628/4885HSD17B10 1542/4885 |
| US-20230103271-A2 | NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE | GNRHR, GIPR, UGT1A7 | LMNA 954/4885PKM 4001/4885HSD17B10 1074/4885 |
| US-20190016756-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, EPB41 | LMNA 4748/4885PKM 4048/4885HSD17B10 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.